Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

boiron, messimy array - 51019 delphinium staphisagria - dilutio homeopathica - granule - 3k-10mk - homeopatika (ČeskÁ atc skupina)

Evropská unie - čeština - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sanofi pasteur, lyon array - 13899 inaktivovanÝ virus hepatitidy a - injekční suspenze v předplněné injekční stříkačce - 160eu - hepatitida a, inaktivovanÝ celÝ virus

Evropská unie - čeština - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - roztroušená skleróza - selektivní imunosupresiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropská unie - čeština - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ibsa slovakia s.r.o., bratislava array - 167 betamethason-valerÁt - léčivá náplast - 2,25mg - betamethason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ibsa slovakia s.r.o., bratislava array - 14630 diklofenak-epolamin - léčivá náplast - 140mg - diklofenak

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ibsa slovakia s.r.o., bratislava array - 14630 diklofenak-epolamin - léčivá náplast - 180mg - diklofenak

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

medochemie ltd., limassol array - 15542 monohydrÁt pramipexol-dihydrochloridu - tableta - 0,088mg - pramipexol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

medochemie ltd., limassol array - 15542 monohydrÁt pramipexol-dihydrochloridu - tableta - 0,18mg - pramipexol